Bacillus Calmette-Guérin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene

BJU Int. 2009 Dec;104(11):1766-73. doi: 10.1111/j.1464-410x.2009.08703.x.

Abstract

To determine whether dendritic cells (DC) transduced with the prostate-specific antigen (PSA) gene can induce PSA-specific cytotoxic lymphocytes (CTL) against prostate cancer cells, and whether bacillus Calmette-Guérin (BCG) cell-wall skeleton (CWS) can enhance the maturation of DC-PSA and the killing activity of subsequently induced PSA-specific CTL. MATERIALS AND METHODS; We generated an adenovirus encoding the PSA gene (AxCA-PSA) using the cosmid-terminal protein complex method. DC were infected with AxCA-PSA using the centrifugal method. The ability of CTL to lyse target cells expressing PSA, i.e the PSA-positive prostate cancer cell line, LNCap, and PSA-transduced autologous phytohaemagglutinin (PHA) blasts expressing PSA, was assessed using the 51Cr-release assay. The maturation of DC-PSA stimulated by BCG-CWS was assayed by flow cytometry. The cytotoxic activity enhanced by BCG-CWS was assessed by the 51Cr-release assay.

Results: DC-PSA induced PSA-specific CTL with 85% cytotoxic activity against LNCaP (effector: target ratio, E:T, of 50:1). However, the cytotoxic activity against PSA-negative cells was very low. Anti-CD8 and anti-major histocompatibility (MHC) class I antibodies blocked PSA-specific cytotoxicity. The PSA-specific killing was reproducible against autologous PHA blast cells expressing PSA, independently of human leukocyte antigen haplotype. Furthermore, the combination of DC-PSA with BCG-CWS remarkably enhanced the PSA-specific cytotoxicity against PHA blasts expressing PSA (15-30% at an E:T ratio of 50:1).

Conclusion: These findings suggest that DC-PSA can induce MHC class I-restricted PSA-specific CD8+ CTL responses and that DC-PSA matured by BCG-CWS enhance PSA-specific cytotoxicity. The combination of DC-PSA with BCG-CWS might be a useful approach for treating advanced prostate cancer.

MeSH terms

  • Adenoviridae / genetics
  • CD8 Antigens / immunology
  • Cell Line, Tumor
  • Cell Wall Skeleton / immunology
  • Cell Wall Skeleton / pharmacology*
  • Dendritic Cells / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • Genetic Therapy / methods
  • Genetic Vectors
  • Histocompatibility Antigens Class I / immunology
  • Humans
  • Immunotherapy / methods
  • Male
  • Mycobacterium bovis*
  • Prostate-Specific Antigen / genetics*
  • Prostatic Neoplasms / therapy*
  • T-Lymphocytes, Cytotoxic / physiology*
  • Transduction, Genetic

Substances

  • CD8 Antigens
  • Cell Wall Skeleton
  • Histocompatibility Antigens Class I
  • Prostate-Specific Antigen